AMG 223

DRUG2 trials

Sponsors

Amgen, Amgen Research (Munich) GmbH

Conditions

Chronic Kidney DiseaseEnd Stage Renal DiseaseHealthy VolunteersHyperphosphatemicKidney Disease

Phase 1

A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)

CompletedNCT00756860

Amgen Research (Munich) GmbHHealthy Volunteers

Start: 2008-05-31End: 2009-09-30Updated: 2012-06-04

Phase 2

Study to Assess Fixed Dosing of AMG 223 in Subjects With Chronic Kidney Disease on Hemodialysis With Hyperphosphatemia

CompletedNCT00530114

AmgenChronic Kidney Disease, End Stage Renal Disease, Hyperphosphatemic +1

Start: 2008-03-31End: 2009-02-28Updated: 2016-03-14